Vivani Medical

Q2 FY2026 EarningsQ2 FY2026 results were slightly better than consensus: net loss of $6.37M vs. $6.84M expected, and GAAP EPS of -$0.07 vs. -$0.08 expected. As a clinical-stage biopharmaceutical company, revenue remained $0, in line with expectations. The performance was driven by lower-than-anticipated operating expenses in both the Biopharm and Neurostimulation divisions. Management successfully completed dosing for the SLIM-1 trial of NPM-139, with topline data expected in November 2026, though a 'going concern' warning remains due to a cash runway extending only through Q2 2027.